Compounding Pharmacy · Est. 2009 · Houston, TX · Both

Empower Pharmacy Review

Empower Pharmacy is a Houston-based compounder that runs a 503A pharmacy and Empower Pharma, an FDA-registered 503B outsourcing facility it describes as the nation's largest; a second Empower 503B site in East Windsor, New Jersey is also registered with FDA. Empower supplies compounded semaglutide and tirzepatide to many of the nation's largest telehealth brands and operates its 503B under cGMP requirements. FDA issued warning letters to both the 503B and the 503A in April 2025, and a September 2026 warning letter to the 503A said some of its compounded semaglutide and tirzepatide products appear to be essentially copies of FDA-approved drugs.

In its September 2026 warning letter to Empower's 503A pharmacy, FDA said the pharmacy's semaglutide/cyanocobalamin and tirzepatide/niacinamide products appear to be essentially copies of approved drugs, the question our compounded semaglutide status tracker follows. Because Empower runs both a 503A pharmacy and a 503B outsourcing facility in Houston, patients of a program such as Eden can ask which Empower site fills their order. Our news report on the letter goes through what FDA said about the two blends.

6 FDA, state or legal actions on record. Most recent: FDA warning letter (Sep 18, 2026) — see the full record below.

WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. How we make money

BothPCABcGMPFDA Registered 503BLegitScript
Location: Houston, TX
States licensed: 49
9.1/10
★★★★★4.6/5

Editorial score out of 10 · methodology

Regulatory Actions

FDA Warning Letter (516718) about Empower's former 12123 Jones Rd facility after a 2015 inspection: no valid patient-specific prescriptions for a portion of products and serious deficiencies in sterile drug production. FDA's 2018 close-out notes the firm ceased operations there on April 2, 2016.
FDA Warning Letter (613792) to the 503B outsourcing facility after a Feb 12-Mar 6, 2020 inspection: drug products failed to meet the conditions of section 503B of the FDCA.
FDA Warning Letter (700962) to Empower Pharma, the 503B outsourcing facility at 5980 W Sam Houston Pkwy N, after an Aug 1-28, 2024 inspection: drug products failed to meet section 503B conditions, and FDA cited serious deficiencies in sterile drug production that put patients at risk.
FDA Warning Letter (700964) to the 503A pharmacy at 7601 N Sam Houston Pkwy W after a Sep 24-Oct 4, 2024 inspection: FDA cited serious deficiencies in drug production practices that put patients at risk (Form 483 issued October 4, 2024).
FDA's outsourcing-facility list shows the Empower Pharma 503B was last inspected 11/14/2025 with a Form 483 issued; FDA issued a response letter on 6/3/2026.
FDA Warning Letter (738238) to the 503A pharmacy at 7601 N Sam Houston Pkwy W after a Nov 3-14, 2025 inspection: FDA said compounded tirzepatide/niacinamide and semaglutide/cyanocobalamin products appear to be essentially copies of FDA-approved semaglutide and tirzepatide products, and cited serious deficiencies in drug production practices (Form 483 issued November 14, 2025).

Telehealth Providers Sourcing From This Pharmacy

These telehealth brands are reported to fulfill some or all compounded GLP-1 prescriptions through Empower Pharmacy. Sourcing arrangements can change over time.

7.2/ 10
Partner

Eden

Best for: compounded semaglutide or tirzepatide at one flat monthly price that doesn't rise with your dose

★★★★☆3.6/5

Editorial score · methodology

$99/mosemaglutide
$129/motirzepatide
CompoundedSemaglutideTirzepatideGHK-CuGlutathioneFDA Warning
Get StartedRead full Eden review →
7.8/ 10

Lavender Sky Health

Best for: comparing compounded GLP-1 plans across 11 named pharmacies, paying per consult with no membership

★★★★☆3.9/5

Editorial score · methodology

$139/mosemaglutide
see plan details
$139/motirzepatide
see plan details
SemaglutideTirzepatide
7.7/ 10

Mochi Health

Best for: insurance help for brand-name GLP-1s, or self-pay compounded GLP-1 priced by dose

★★★★☆3.9/5

Editorial score · methodology

$139/mosemaglutide
+ added fee
$169/motirzepatide
+ added fee
SemaglutideTirzepatide
7.5/ 10

Hers

Best for: women who want brand-name GLP-1s only, including the Wegovy pill and Foundayo, with a Hers membership

★★★★☆3.8/5

Editorial score · methodology

$149/mosemaglutide
+ required membership
SemaglutideTirzepatideOrforglipronFDA Warning
7.1/ 10

Hims

Best for: people who want brand-name GLP-1 pills or pens through a big-name app with 24/7 messaging

★★★★☆3.6/5

Editorial score · methodology

$149/mosemaglutide
+ required membership
SemaglutideTirzepatideOrforglipronFDA Warning
7.1/ 10

NexLife

Best for: quality-conscious patients wanting LegitScript + NABP-certified GLP-1

★★★★☆3.6/5

Editorial score · methodology

$109/mosemaglutide
$129/motirzepatide
SemaglutideTirzepatideFDA Warning

Certifications & Compliance

All sterile compounding pharmacies in the United States are required to follow United States Pharmacopeia General Chapter <797> sterile compounding standards[4], with finished preparations evaluated against USP <71> sterility testing[5] and USP <85> bacterial endotoxin testing[6] as appropriate for the product type.

PCAB
Pharmacy Compounding Accreditation Board — voluntary third-party accreditation (operated by ACHC) auditing the pharmacy against nationally recognized quality and safety standards for sterile and non-sterile compounding.
cGMP
Current Good Manufacturing Practices — the FDA standard used by pharmaceutical manufacturers, required of 503B outsourcing facilities.
FDA Registered 503B
Registered directly with the FDA as a 503B outsourcing facility. Subject to FDA inspection and required to follow cGMP standards.
LegitScript
LegitScript Healthcare Merchant certification — third-party vetting of the pharmacy's licensure, prescription requirements, and marketing practices; required by most ad platforms before a pharmacy can advertise.

Drugs Produced

Compounding pharmacies' ability to produce semaglutide or tirzepatide depends on the FDA Drug Shortage List status for each reference product; compounding eligibility can change when a drug moves on or off the shortage list[7].

Semaglutide
Compounded semaglutide produced
Tirzepatide
Compounded tirzepatide produced

States Licensed (49)

ALAKAZARCOCTDEFLGAHIIDILINIAKSKYLAMEMDMAMIMNMSMOMTNENVNHNJNMNYNCNDOHOKORPARISCSDTNTXUTVTVAWAWVWIWY

External Reviews

Google Reviews
3.5 / 5.0
Based on 420 reviews

Weight Loss Rankings Score Breakdown

Accreditation & Compliance9/10
Regulatory Standing5/10
State Coverage10/10
GLP-1 Production10/10
Track Record9/10

Scores are independently researched. See our methodology for details.

High confidence · Pharmacy details last verified November 2026 · How we verify provider data

Frequently Asked Questions

Empower Pharmacy is a Both compounding pharmacy based in Houston, TX that has been operating since 2009. It holds PCAB accreditation, a voluntary third-party quality standard for compounding pharmacies. Note: our records show 6 documented regulatory action(s) — see the Regulatory Actions section below.
Empower Pharmacy is headquartered in Houston, TX. The pharmacy is licensed to ship to 49 US states.
Empower Pharmacy produces compounded semaglutide and compounded tirzepatide in addition to other compounded preparations. As a Both pharmacy, it operates both a patient-specific 503A division and an FDA-registered 503B outsourcing facility.
503A pharmacies prepare compounded medications for individual patients in response to specific prescriptions and are regulated primarily by state boards of pharmacy under USP <797> sterile compounding standards. 503B outsourcing facilities register directly with the FDA, follow current Good Manufacturing Practices (cGMP), and can produce compounded medications in larger batches without patient-specific prescriptions. 503B facilities are subject to FDA inspection.

Key terms, explained

New to GLP-1s? Tap any term for a quick, plain-English definition.

Sources & methodology (as of November 2026)
  1. 1.FDA — Compounding and the 503A Pharmacy Framework— U.S. Food & Drug Administration.
  2. 2.FDA — 503B Outsourcing Facility Registration and Requirements— U.S. Food & Drug Administration.
  3. 3.PCAB — Pharmacy Compounding Accreditation Board Standards— Accreditation Commission for Health Care (ACHC) / PCAB.
  4. 4.USP General Chapter <797> — Pharmaceutical Compounding: Sterile Preparations— United States Pharmacopeia.
  5. 5.USP General Chapter <71> — Sterility Tests— United States Pharmacopeia.
  6. 6.USP General Chapter <85> — Bacterial Endotoxins Test— United States Pharmacopeia.
  7. 7.FDA — Drug Shortages Database (current shortage listings)— U.S. Food & Drug Administration.